UPDATE 1-FDA reviewers support Celltrion's biosimilar Remicade
February 05, 2016 at 08:17 AM EST
Feb 5 (Reuters) - U.S. Food and Drug Administration staff members on Friday said clinical data from Celltrion Inc's biosimilar form of blockbuster arthritis drug Remicade indicated it is "highly similar" to the branded product in terms of safety, purity and potency.